Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic mutations are present in all members of the AKT family in endometrial carcinoma

8 Sept 2009

Abstract excerpt

The activating E17K mutations recently discovered in the pleckstrin homology domain of AKT1 in about 2% of endometrial cancer patients ( Shoji et al, 2009 ) suggest a new mechanism for PI3 kinase pathway activation in these patients, as previously described in breast, colorectal and ovarian cancers ( Carpten et al, 2007 ). Additional mechanisms of PI3 kinase pathway activation in endometrial cancer include the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to PI3K/AKT/mTOR signaling in cancer
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19738612
DOI: 10.1038/sj.bjc.6605301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutations are present in all members of the AKT family in endometrial carcinomaPMID 19738612Read ↗

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.Semantic proximity Read ↗

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.Semantic proximity Read ↗

Reply: Somatic mutations are present in all members of the AKT family in endometrial carcinomaSemantic proximity Read ↗

Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.Semantic proximity Read ↗

Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.Semantic proximity Read ↗

Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.Semantic proximity Read ↗

Association Between Genetic Variants of Akt1 and Endometrial Cancer.Semantic proximity Read ↗

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.Semantic proximity Read ↗

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.Semantic proximity Read ↗

Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.Semantic proximity Read ↗

Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.Semantic proximity Read ↗

Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.